Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the
treatment of advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only …

Vismodegib (Erivedge®) is the first-in-class, oral small molecule inhibitor of the Hedgehog
(Hh) pathway, abnormal activation of which is associated with basal cell carcinoma (BCC) …

Basal cell carcinoma (BCC) accounts for almost 80% of skin cancers, and its healthcare
workload burden is substantial within dermatology departments. Although most BCCs are …

Introduction Basal cell carcinoma (BCC) is the most common malignant tumor in adult white
populations. If BCCs are not treated for years, if they cause massive destruction of the …

Valemetostat is an EZH2/1 inhibitor that has been approved in Japan for the treatment of
patients with relapsed/refractory adult T‐cell leukemia/lymphoma, based mainly on results …

Abstract Purpose Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of
advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of …

Predicting human pharmacokinetics (PK) during the drug discovery phase is valuable to
assess doses required to reach therapeutic exposures. For orally administered compounds …

Abstract The US Food and Drug Administration (FDA) issued a guidance document in 2010
on pharmacokinetic (PK) studies in renal impairment (RI) on the basis of observations that …

Vismodegib displays unique pharmacokinetic characteristics including saturable plasma
protein binding to alpha-1 acid glycoprotein (AAG) and apparent time-dependent …

Glasdegib is an inhibitor of the Hedgehog pathway recently approved in the United States
for the treatment of acute myeloid leukemia. A population pharmacokinetic analysis was …